|
Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.
PMID 42441931 · Neurol Neuroimmunol Neuroinflamm · 2026-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes.
PMID 42119725 · Ann Vasc Surg · 2026-Sep
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
PMID 42208561 · Lancet · 2026-May-30
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
PMID 42208560 · Lancet · 2026-May-30
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
PMID 41865758 · Lancet · 2026-May-30
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Intensive Versus Conventional Blood Pressure Lowering After Successful Endovascular Thrombectomy: OPTIMAL-BP 1-Year Outcomes.
PMID 42212393 · Stroke · 2026-May-29
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.
PMID 41206702 · Clin Exp Dermatol · 2026-May-26
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.
PMID 42192627 · BMJ Open · 2026-May-24
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
PMID 42150581 · Lancet · 2026-May-23
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
PMID 42000149 · Vaccine · 2026-May-22
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.
PMID 42167880 · Lupus Sci Med · 2026-May-21
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
PMID 42163822 · Acta Derm Venereol · 2026-May-21
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.
PMID 42163196 · BMC Oral Health · 2026-May-20
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.
PMID 41560517 · Clin Infect Dis · 2026-May-20
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.
PMID 42132192 · J Am Heart Assoc · 2026-May-19
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.
PMID 41697953 · Br J Dermatol · 2026-May-19
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.
PMID 41692601 · Aesthet Surg J · 2026-May-18
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.
PMID 42134354 · Lancet · 2026-May-16
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.
PMID 42114550 · Lancet · 2026-May-16
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Feasibility, acceptability and efficacy of a nurse-led palliative care health coaching intervention (Educate, Nurture, Advise before Life Ends) for patients with heart failure and their caregivers in Singapore: a randomised wait-list controlled pilot study of health coaching in Asian heart failure.
PMID 42152453 · BMJ Open · 2026-May-15
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
PMID 42150214 · Breast · 2026-May-14
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
PMID 42127391 · N Engl J Med · 2026-May-14
The study is a Phase III randomized trial of a drug (telitacicept) in humans, but it is not an oncology study; it evaluates IgA nephropathy. Furthermore, the primary endpoint is a surrogate biomarker (proteinuria reduction), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
|
H
L
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
PMID 42127390 · N Engl J Med · 2026-May-14
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
A Phase 3 Trial of Brepocitinib in Dermatomyositis.
PMID 41910335 · N Engl J Med · 2026-May-14
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
PMID 42128454 · BMJ · 2026-May-13
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.
PMID 42119607 · J Natl Compr Canc Netw · 2026-May-12
The study is a randomized Phase III trial with a drug intervention (hydromorphone vs. morphine) in oncology patients. However, the primary efficacy endpoint is pain relief measured by the Numeric Rating Scale (NRS), which is not a time-to-event outcome (e.g., OS, PFS, DFS). No Kaplan-Meier curves or hazard ratios for time-to-event endpoints are reported.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.
PMID 41984450 · JAMA · 2026-May-12
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension.
PMID 41670573 · J Am Coll Cardiol · 2026-May-12
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).
PMID 42103705 · Nat Commun · 2026-May-08
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.
PMID 42090793 · N Engl J Med · 2026-May-07
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
PMID 42090792 · N Engl J Med · 2026-May-07
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
PMID 41910380 · N Engl J Med · 2026-May-07
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Clobetasol Propionate Ophthalmic Suspension to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery.
PMID 42097332 · Ophthalmology · 2026-May-05
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
PMID 41838419 · Rheumatology (Oxford) · 2026-May-05
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.
PMID 42082491 · Nat Commun · 2026-May-04
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Hematoma Interleukin-1 Receptor Antagonist Concentrations Predict Long-Term Outcome in Acute Human Intracerebral Hemorrhage.
PMID 42071280 · Ann Neurol · 2026-May-03
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.
PMID 42030965 · Lancet · 2026-May-02
未发现恶性肿瘤人群证据。
|
H
L
B
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial.
PMID 42101839 · JAMA Netw Open · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.
PMID 41974026 · Hepatol Commun · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.
PMID 41860544 · JAMA Neurol · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial.
PMID 41860533 · JAMA Neurol · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).
PMID 41738176 · Am J Respir Crit Care Med · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Phase III cardiac rehabilitation improves left ventricular ejection fraction in patients with coronary artery disease and mildly reduced ejection fraction after percutaneous coronary intervention.
PMID 41662912 · Int J Cardiol · 2026-May-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.
PMID 41369302 · Int Clin Psychopharmacol · 2026-May-01
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.
PMID 42157574 · Eur J Neurol · 2026-May
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial.
PMID 42149110 · Microb Genom · 2026-May
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.
PMID 42130156 · J Clin Hypertens (Greenwich) · 2026-May
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.
PMID 42128580 · J Card Fail · 2026-May
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.
PMID 42104877 · United European Gastroenterol J · 2026-May
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.
PMID 42104207 · Expert Opin Biol Ther · 2026-May
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|